Wendy Barnes

Stay informed with Wendy Barnes’s coverage and analysis for Fortune.

  • Wendy BarnesCommentary

    I’m the CEO of GoodRx. A new era of access demands smarter design for direct-to-consumer drug pricing

    By
  • Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.Commentary

    The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up

    By